adesso (ADN1) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
15 May, 2026Executive summary
Sales revenue grew 12% year-over-year to EUR 709.5 million in H1 2025, driven by organic expansion and strong demand for digitalization services.
EBITDA increased 34% to EUR 37.2 million, with margin improving to 5.2% from 4.4% in H1 2024.
Net loss narrowed to EUR -6.0 million from EUR -9.9 million, and EPS improved to EUR -0.88 from EUR -1.51 year-over-year.
Employee headcount rose 7% to over 10,700 FTEs, supporting business growth and recognized as a top employer.
Full-year guidance reaffirmed, expecting revenue of EUR 1.35–1.45 billion and EBITDA of EUR 105–125 million.
Financial highlights
Domestic sales grew 14% while international sales rose 6% year-over-year; Q2 revenue grew 13% to EUR 356 million.
Gross profit increased 10% to EUR 598.0 million; personnel costs up 10% to EUR 493.7 million.
Free cash flow was negative at EUR -80.8 million, impacted by negative operating cash flow and CapEx.
Equity ratio declined to 21.5% from 24.2% at year-end 2024.
Net working capital rose 10% to EUR 226.0 million.
Outlook and guidance
On track to achieve full-year revenue guidance of EUR 1.35–1.45 billion and EBITDA of EUR 105–125 million, with margin target above 7.6%.
Earnings expected to be weighted toward H2 2025 due to more working days and increased IT spending, especially in the public sector.
Management expects higher earnings in H2 2025, supported by order backlog and new opportunities in defense and infrastructure.
IT services and software markets are expected to grow steadily, with sector-specific growth outpacing general economic trends.
Latest events from adesso
- 14% sales growth and higher EBITDA in 2024, with 2025 guidance projecting further gains.ADN1
H2 202415 May 2026 - Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 202611 May 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025